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A B S T R A C T
Congenital heart diseases (CHDs) are the most common birth defects among life births, which could be presented
as isolated or syndromic with other congenital malformations. The etiology of CHD largely unknown, genetic
and environmental factors contribute to the disease. Recurrent copy number variants (CNVs) have been reported
in the pathogenesis of CHD. The aim of this study was to evaluate the clinical utility of multiplex ligation-
dependent probe amplification (MLPA) and microarray analyses on isolated and syndromic CHD cases and to
explore the relationship between identified CNVs and CHD. Eighteen prenatal samples, 16 isolated and 33
syndromic patients with mild to severe CHD phenotype were tested. Prenatal and isolated CHD cases did not
show pathogenic CNVs. Clinically significant CNVs were detected in 7/33 (21%) syndromic CHD patients: del
22q11.2 (n= 2), 8p23.1 duplication (n=2), deletion 5p (n=1), deletion 6q21q22 (n= 1), unbalanced
translocation causing partial deletion of 4q34.3 and duplication of 6q25.1 (n=1). These genomic imbalances
contain genes that has been associated with human CHD before. The present study demonstrates that using
microarray and MLPA analysis increase the detection rate of causal CNVs in individuals with syndromic CHD.
1. Introduction
Congenital heart diseases (CHDs) refers to structural anomalies of
the heart and blood vessels that arise during cardiac embryogenesis and
differ in morphology, physiology, functional and clinical outcomes.
Current epidemiological data indicate that CHD is the most common
birth defect, affecting 10–12/1000 liveborn infants and one of the
major causes of the perinatal morbidity and mortality. The successful
medical and surgical management of even severe CHD cases greatly
increased the survival of affected individuals and contribute to a large
extent to its increased prevalence among older children and adults
(Hoffman et al., 2004; van der Linde et al., 2011).
Congenital heart defects represent a broad spectrum of malforma-
tions, including septal and valve defects, lesions affecting the outflow
tract and ventricules. Simple defects have been defined as atrial septal
defect (ASD), ventral septal defect (VSD), patent ductus arteriosus
(PDA), pulmonary stenosis (PS), foramen ovale apertum (FoA), and in
general they have good prognosis. The complex and more severe forms,
that is Tetralogy of Fallot (TOF), univentricular heart, hypoplastic left
heart (HLH) most frequently require multiple surgical correction pro-
cedures if at all possible, and have uncertain long-term outcomes.
Patients can be classified as having apparently isolated CHD without
identifiable congenital malformations in other organ system or syn-
dromic CHD with extracardiac manifestations, such as dysmorphic
features, growth retardation, developmental delay and major structural
malformations (Fahed et al., 2013). As survival of patients with CHD
has improved, there has been an increased need to reveal of its etiology,
understanding patient-specific risk factors that influence outcomes and
comorbidities. CHD pathogenesis is still largely unknown, it is widely
accepted that genetic and non-genetic factors play an important role in
its etiology. About 80% of CHDs are isolated cases with multifactorial
inheritance and 20% has genetic origin. Over the past few decades our
knowledge has expanded about the genetic factors that contribute to
CHDs (Blue et al., 2012; Pierpont et al., 2007). Chromosomal
https://doi.org/10.1016/j.jbiotec.2019.04.025
Received 31 January 2019; Received in revised form 17 April 2019; Accepted 29 April 2019
⁎ Corresponding author at: Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98.,
Debrecen, H-4032, Hungary.
E-mail address: ujfalusi.aniko@med.unideb.hu (A. Ujfalusi).
Journal of Biotechnology 299 (2019) 86–95
Available online 01 May 2019
0168-1656/ © 2019 Published by Elsevier B.V.
T
aneuploidies as the first recognized genetic causes of CHD are con-
tinuously the major etiological factors that accounts for 8–19% of cases.
CHD is observed in 35–50% of liveborns with trisomy 21, 60–80% of
liveborns with trisomy 13 and trisomy 18, and 33% with monosomy X
(Hartman et al., 2011). Submicroscopic copy number variations (CNVs)
refer to structural aberrations containing deletions and duplications
ranging in size between 1 kb to several megabases leading to altered
dosage of contiguous genes and produce mainly syndromic CHD. Well-
characterized CNV induced syndromes are the DiGeorge/Velocardio-
facial syndrome (del 22q11), Williams syndrome (del 7q11) and 8p23.1
deletion syndrome. Recent studies of larger cohorts of patients de-
scribed new, recurrent CNVs associated with CHD, including 1q21.1,
3p25.1, 16p13.11, 15q11.2 and 2p13.3 (Breckpot et al., 2010; Glessner
et al., 2014; Goldmuntz et al., 2011). In addition to specific syndromes,
an increased burden of CNVs was also identified in patients with iso-
lated CHD. These studies estimate that 5–10% of sporadic, non-syn-
dromic CHD cases are due to certain rare CNVs (Erdogan et al., 2008;
Hanchard et al., 2017; Soemedi et al., 2012). Monogenic causes of CHD
was initially investigated in multigeneration pedigrees using linkage
analysis. Some of the genes first identified are cardiac transcription
factors that include NKX2.5, GATA4, TBX5, TBX1, MEF2, ZIC3
(Prendiville et al., 2014). In addition to these regulators, genes coding
for proteins in Notch and RAS signaling pathway, chromatin re-
modeling, cilia function, sarcomere structure have been identified in
the last decade. Genome-wide and high-throughput sequencing tech-
niques have determined that 10% of CHD is caused by de novo coding
variants, the proportion being even higher in syndromic forms, ac-
counting for 20% of cases (Homsy et al., 2015; Zaidi and Brueckner,
2017). DNA microarray has been widely used in clinical practice for
evaluation of causative genomic imbalances in mental retardation and
major congenital abnormalities (Battaglia et al., 2013). It is proved to
be a powerful technique for genetic investigation of CHD patients also.
Application of array CGH allows genome-wide detection of submicro-
scopic CNVs involving loci and genes with known roles in cardiac de-
velopment and may also identify candidate genes related to CHD
(Shanshen et al., 2018). Multiplex ligation-dependent probe amplifi-
cation (MLPA) is a multiplex PCR method, detecting small scale CNVs,
partial deletions/duplications of specific genes. It is widely used for the
validation of array CGH results and screening CNVs in known genes.
Compared to microarray, MLPA has a low cost and advantage of easy to
use. The inclusion of MLPA in clinical settings as a complementary or
screening method can significantly increase the detection rate of CNVs
(Monteiro et al., 2017; Sorensen et al., 2012).
The aim of this study was to use whole-genome array CGH and
MLPA analysis to identify rare CNVs responsible for isolated and syn-
dromic CHD and to evaluate the clinical utility of these techniques in
prenatal and postnatal CHD cases. To our knowledge this is the first
study for investigation of CNVs in CHD using array CGH and MLPA in
Hungary.
2. Materials and methods
2.1. Patients
Two independent patient cohorts were obtained for this study. The
first cohort consisted of 18 ventricular myocardium samples from
aborted fetuses with heart defects. The samples were recruited from the
First Department of Obstetrics and Gynecology, Semmelweis
University, Budapest. In the prenatal study group, the average gesta-
tional age was 20.85 weeks. All of the samples were obtained from
terminated pregnancies. The diagnosis was made by ultrasound ex-
amination and echocardiography. Each cardiac malformation was
confirmed by fetal pathology. The phenotypic details of this cohort are
summarized in Table 1. The second cohort contained 33 syndromic and
16 isolated CHD cases. The patients were referred mainly from the
Clinical Genetic and Cardiology outpatient clinics at the Department of
Pediatrics, University of Debrecen, Debrecen. The ages of patients
tested ranged from 2 to 18 years in syndromic CHD patient group and
from 10 months to 46 years in the isolated CHD group. Peripheral blood
samples were taken from probands after obtaining informed consent
from the affected individuals or from their parents according to the
national regulations.
2.2. Study design
The aim of the study was to identify pathogenic CNVs in syndromic
and isolated CHD cases with unknown etiology and to determine gen-
otype-phenotype correlations. The sequence and priority of the genetic
tests applied largely depended on the patients’ phenotype and their
severity. In general, any patient with a CHD with or without accom-
panying symptoms (developmental delay, dysmorphism) underwent a
G-banded karyotyping, if normal, and there was a suspicion of a
common microdeletion, we applied region-specific fluorescence in situ
hybridization or MLPA analysis. In case of negative results, array CGH
was performed after a careful evaluation and patient selection.
2.3. Cytogenetic analysis
Chromosome analysis was performed on G-banded metaphases
prepared from cultured peripheral blood according to standard proto-
cols. The karyotypes were described according to the International
System for Human Cytogenetic Nomenclature (ISCN) 2016.
2.4. Fluorescence in situ hybridization (FISH)
FISH was done according to the manufacturer’s recommendations
using DiGeorge/VCFS TUPLE1 probe, Subtelomer (4p/4q, 6p/6q) spe-
cific probes, Cri-du-chat and SOTOS probe combination (Cytocell,
Rainbow Scientific Inc., Windsor, CT). For multicolor FISH analysis
24XCyte probe was used (MetaSystems, Altlussheim, Germany).
Metaphases were analyzed by Zeiss Axioplan 2 fluorescence microscope
and Isis software was used for image capturing and processing
(MetaSystems, Altlussheim, Germany).
2.5. DNA isolation
Genomic DNA was isolated from peripheral blood samples of all
patients and from ventricular tissues of abortions using QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany). NanoDrop 2000/2000c
UV–vis spectrophotometer (ThermoFisher Scientific, Waltham,
Massachusetts, US) was used to determine the quantity and quality of
DNA.
2.6. Multiplex ligation-dependent probe amplification (MLPA)
MLPA was performed using SALSA MLPA P250-B2 DiGeorge and
SALSA MLPA P311-B1 Congenital Heart Disease probemixes (MRC-
Holland, Amsterdam, The Netherlands) according to the manufacturer’s
protocol. The P250-B2 DiGeorge kit includes 48 probes: 29 probes are
located in the 22q11.2 region and can be used to distinguish the most
common types of deletion and 19 probes are present for relevant re-
gions of DiGeorge syndrome (DGS), DGS type II or disorders with
phenotypic features of DGS on 22q13 and on chromosomes 4q35, 8p23,
9q34.3, 10p14 and 17p13.3. The P311-B1 kit identifies copy number
variations in the following genes and regions previously associated with
CHD: GATA4 (8p23), TBX5 (12q24), NKX2.5 (5q35), BMP4 (14q22),
CRELD1 (3p25) and 22q11.2.
Data were analyzed by Coffalyser Software from MRC-Holland
(Amsterdam, The Netherlands). The results were considered abnormal
when the ratio was< 0.65 for loss or> 1.30 for gain of genetic ma-
terial.
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2.7. Whole genome array comparative genomic hybridization (CGH)
Array CGH was performed using the Affymetrix CytoScan 750 K
Array. Genomic DNA samples were digested, ligated, amplified, frag-
mented, labeled, and hybridized to the CytoScan 750 K Array platform
as specified by the manufacturer. The raw data were analyzed by ChAS
v2.0 Software (Affymetrix, Thermo Fisher Scientific, Waltham, MA) and
CNVs were called and based on human assembly GRCh37 (hg19). FISH
and MLPA techniques were applied for validation of the array results.
2.8. Data analysis
We analyzed those CNV calls that involved at least 10 probes for
deletion and 20 for duplication. For interpretation of the detected CNV
calls we have used freely available websites and databases: Database of
Genomic Variants (DGV), UCSC Genome Browser, Database of
Chromosomal Imbalance, Phenotype of Humans using Ensemble
Resources (DECIPHER), ISCA, PubMed, Online Mendelian Inheritance
in Man (OMIM). Identified CNVs were interpreted and classified ac-
cording to the standards and guidelines of the American College of
Medical Genetics (ACMG) (Kearney et al., 2011). Additionally, the loss
of heterozygosity (LOH) along the genome was investigated. Those
regions that showed ≥10 Mb LOH were analyzed to verify the possible
effect of imprinting.
3. Results
3.1. Prenatal cases
The CHD phenotypes of the fetuses were very heterogeneous.
Simple ventricular septal defect was determined in only two cases. In
13/18 fetuses the septal defect was associated with other structural
malformations of the heart (transposition of great arteries, hypoplasia
of the ventricles and/or great arteries, dilatation of ventricules). Two
fetuses showed TOF, one case had univentricular heart (Table 1.). All
18 cases were successfully analyzed using P250-B2 and P311-B1 MLPA
probemixes. Seventeen samples did not show pathological CNVs in the
examined genes and regions. In one case we identified a duplication
involving four consecutive probes, specific for exon 1, intron 1, exon 3
and 4 of the BMP4 gene.
3.2. Syndromic CHD cases
In the syndromic cohort the CHD phenotypes were similarly diverse,
ranging from simple to complex: ASD/VSD (n=12), TOF (n=8), FoA
(n= 3), PDA (n=1), PS (n=1), univentricular heart (n=1), situs
inversus totalis (n= 1), other complex (n=6) cardiac malformations.
In this cohort the extracardiac symptoms described by clinical geneti-
cist represented a broad spectrum of malformations associating with the
CHD.
A total of 33 affected patients with syndromic CHD were referred for
genetic studies. Conventional chromosome analysis was performed in
32/33 cases, 94 percent of analysed cases (30/33) showed normal
karyotype, in two patients numerical and structural chromosome
aberrations were identified (Case No 1. and 2.). DiGeorge region spe-
cific FISH was carried out on 10/33 samples, none of them showed
deletion of the 22q11.2 region. Microarray was applied in 25/33 cases.
A total of four patients presented pathogenic CNVs, thus the detection
rate of array CGH was 16% (4/25). In the remaining 8 cases only MLPA
was performed, in 3 out of 8 samples clinically significant CNV was
identified. Summary of the patients data and results of genetic tests are
shown in Table 2.
Case No 1. had ASD, PDA, microcephaly, hypertelorism, small
mouth, retrognathia, low-set ears, laryngeal hypoplasia, syndactyly II-
III, axial hypotonia and spasticity of the extremities. GTG-banding re-
vealed a ring chromosome derived from chromosome 5 and a super-
numerary small marker chromosome (sSMC). His karyotype was
47,XY,r(5),+sSMC (Fig. 1A). Because of the cat-like cry, Cri du chat
syndrome, also known as 5p deletion syndrome was assumed by the
clinical geneticist. Application of locus specific FISH probe confirmed
the deletion of the 5p15.2 region on the ring chromosome and multi-
color FISH classified the sSMC as a derivative chromosome 15 (Fig. 1B,
C). Microarray analysis detected a 34.58 Mb deletion of 5p15.33p13.2
region. (Fig. 1D) as a sole imbalance. The deleted segment included 65
OMIM genes. No CNV was detected on chromosome 15 indicating the
heterochromatic origin of the sSMC.
Case No 2. presented with TOF, somatic retardation, hypothyreosis
and solitary kidney. Cytogenetic analysis identified an interstitial
Table 1
Summary of data of prenatal samples.
No. Gestational age
(weeks)
Sex Prenatal ultrasound Pathological findings, CHD phenotype
1. 21 M Transposition of the great arteries,
ventricular septal defect
Transposition of the great arteries, ventricular septal defect.
2. 22 F CHD Atrioventricular septal defect. Pulmonary artery stenosis. Dextroposition of the aorta. Single
umbilical artery.
3. 23 F CHD Ventricular septal defect. Hydropericardium. Endomyocardial fibrosis. Pulmonary atresia.
4. 20+3 F CHD Ventricular septal defect. Coarctation of the aorta.
5. 20 M Tetralogy of Fallot Tetralogy of Fallot.
6. 19 M Multiplex malformation Spina bifida cystica. Ventricular septal defect. Urethral obstruction. Congenital
hydronephrosis. Megaloureter. Omphalocele. Left-sided talipes equinovarus.
7. 22 M CHD Transposition of the aorta, ventricular septal defect, hypoplastic aortic arch.
8. 19 F CHD Ventricular septal defect, hypoplastic left heart, dilatation of right heart.
9. 21 M Multiplex malformation Univentricular heart. The aorta originating ventrally from a common ventricle with the
pulmonary artery behind it.
10. 22+4 F Complex CHD Atresia of the ascending aorta, ventricular septal defect.
11. 19+4 M Atrioventricular septal defect Atrioventricular septal defect.
12. 20+3 F CHD Ventricular septal defect, coarctation of the aorta.
13. 20 M Tetralogy of Fallot Tetralogy of Fallot.
14. 21 M CHD Hypoplastic right heart. Hypoplastic pulmonary artery.
15. 21 F CHD Hypoplastic aorta, hypoplastic left heart.
16. 21 F CHD Hypoplastic aorta, hypoplastic left heart. Dextroposition of the heart.
17. 22 M Multiplex malformation Bilateral hydrothorax. Ascites bilateral. Dilated cardiomyopathy.
18. 19 M Multiplex malformation Congenital hygroma colli. Left-sided talipes equinovarus. Ventricular septal defect. Left-sided
renal and ureteral agenesis.
Note: M-Male, F-Female, CHD-congenital heart defect.
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deletion of the long arm of chromosome 6 with presumed breakpoints
at 6q23 and 6q25. Microarray clarified the size (18.753 kb) and the
exact breakpoints (6q21 and 6q23.2) of the genomic imbalance.
Case No 3. presented with ASD, situs inversus, macrocephaly, somatic
retardation, facial dysmorphism, short and wide neck, brachydactyly,
syndactyly III-IV, narrow chest. Her karyotype was normal. Partial de-
letion and duplication due to unbalanced translocation could be identi-
fied by array CGH: a 12.15 Mb deletion of 4q34.3 region containing 21
OMIM genes and a 16.95 Mb duplication of 6q25.1 region involving 49
OMIM genes. The CNVs were confirmed by FISH using 4q and 6q sub-
telomeric region specific FISH probes. Our patient's karyotype was in-
itially interpreted as normal, however, after microarray results the G-
banded metaphases were reanalyzed and the karyotype was revised.
Genetic evaluation of parental sample revealed that her mother is carrier
of the balanced form of the child’s translocation. The patient’s final
karyotype was thereafter: 46,XX,der(4)t(4;6)(q34.3;q25.1)[15]mat. arr
[hg19]4q34.3q35.2(178,807,365-190,957,460)x1, 6q25.1q27(150,485,
038–167,439,226)x3 (Fig. 2). Genetic counseling was provided on re-
currence risk and prenatal genetic testing was recommended in the
subsequent pregnancies.
Case No 4. presented with coarctation of the aorta, plagiocephaly,
flat occiput, facial dysmorphism: upslanted palpebral fissures, epi-
canthus, long philtrum, retrognathia, low-set ears, low nasal bridge,
hypospadiasis. His karyotype and DiGeorge FISH were normal.
Microarray has shown a 3.842 Mb duplication at 8p23.1 region that
consisted of 17 OMIM genes. The CNV was confirmed by MLPA. His
sister (Case No 5.) was born at 32. weeks of gestation with birth weight
of 1900 g (50th percentile). Her clinical features included hypotonia,
prominent forehead, broad nasal root, epicanthic fold, motor delay and
FoA. In her case only MLPA DiGeorge probemix was used to screen CHD
associated CNVs. Similarly to her brother, 8p23.1 duplication was de-
tected (Fig. 3A).
Case No 6. was initially diagnosed with isolated TOF, therefore
MLPA DiGeorge kit was applied as a first tier test. MLPA identified the
deletion of all consecutive probes that represent the 22q11.2 region
(Fig. 3B).
Case No 7. was referred to the clinical geneticist based on her
congenital heart disease (TOF) and hypoplastic thymus. MLPA analysis
using DiGeorge probemix showed heterozygous deletion of all con-
secutive probes at 22q11.2 region, confirming the diagnosis of
DiGeorge syndrome. The result of MLPA analysis of parental samples
was negative confirming the de novo origin of CNV.
3.3. Isolated CHD cases
The non-syndromic cases (n=16) had mostly severe, complex
CHD: TOF (n= 12), AVSD (n=1), univentricular heart (n=1), hy-
poplastic left heart (n=1), AVSD+ transposition of great arteries
(n= 1). There were no CNVs classified as clinically significant in pa-
tients with apparently isolated CHD.
4. Discussion
The availability of chromosomal microarray testing as a widely used
genetic test has increased the importance of the contribution of CNVs to
CHD. Genomic imbalances not only underlie the structural CHD, but
also are major contributors to CHD comorbidities such as arrythmia,
heart failure, neurocognitive malfunction (Russell et al., 2018).
In the present study we performed genetic investigation of CHD
cases to detect causal CNVs using MLPA and microarray techniques. We
have analyzed prenatal cases with myocardium samples (n=18) from
foetuses with heterogeneous CHDs by MLPA. No obvious disease
causing CNVs were identified in this cohort. In one sample MLPA assay
has detected duplication of the entire BMP4 gene. According to litera-
ture data only loss of function of BMP4 is associated with CHD phe-
notype (Qian et al., 2014).
In the cohort of isolated CHD patients (n=16) application of MLPA
probemixes did not reveal pathogenic CNVs. This result might be due to
the low number of analyzed cases, the generally low frequency (5–10%)
of genomic imbalances in isolated cases and targeted analysis of the
CHD associated genes (Erdogan et al., 2008; Soemedi et al., 2012).
Genome wide investigation of CNVs by microarray is the next step in
the genomic evaluation of our prenatal and isolated CHD patient co-
hort.
Chromosomal screening for deletions/duplications using MLPA and
microarray detected imbalances in 21% (7/33) of syndromic CHD
Table 2
Summary of clinical and genetic data of patients with syndromic CHD.
No. Age/sex CHD Karyotype Array CGH (size) MLPA (genes) CNV Phenotype (OMIM)
1. 3 years/
Male
ASD, PDA 47,XY,r(5),+sSMC arr[hg19]
5p15.33p13.2(113,576-
34,700,951)x1
(34.58 Mb)
not done del Cri du chat syndrome
(MIM # 123450)
2. 9 months/
Male
TOF 46,XY,del(6)(q23q2?5) arr[hg19]
6q21q23.2(113,913,946-
132,667,254)x1
(18.753 kb)
not done del 6q21q22 deletion
syndrome
3. 3.5 years/
Female
ASD, situs
inversus
46,XX
Revised karyotype:
46,XX,der(4)t(4;6)
(q34.3;q25.1)
arr[hg19]
4q34.3q35.2(178,807,365-
190,957,460)x1
6q25.1q27(150,485,038-
167,439,226)x3
(4q: 12.15 Mb)
(6q: 16.95 Mb)
not done del/dup 4q deletion/6q
duplication
syndrome
4. 4.5 years/
Male
CoA 46,XY arr[hg19]
8p23.1(8,093,065-11,935,465)x3
(3.842 kb)
not done dup 8p23.1 duplication
syndrome
5. 22 months/
Female
FoA 46,XX not done PPP1R3B,MSRA, GATA4
,
dup 8p23.1 duplication
syndrome
6. 16 years/
Male
TOF not done not done CLTCL1, HIRA, CDC45, CLDN5, GP1BB,
TBX1, TXNRD2, DGCR8, ZNF74, KLHL22,
MED15, SNAP29, LZTR1
del DiGeorge syndrome
(MIM # 188400)
7. 6 months/
Female
TOF 46,XX not done CLTCL1, HIRA, CDC45, CLDN5, GP1BB,
TBX1, TXNRD2, DGCR8, ZNF74, KLHL22,
MED15, SNAP29, LZTR1
del DiGeorge syndrome
(MIM # 188400)
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patients. Our detection rate is consistent with the reported diagnostic
yield of microarray and MLPA in syndromic CHD. Clinical and research-
based testing suggests that CNVs contribute to about 3–30% of CHD.
Reports vary extensively in the type and sensitivity of the microarray
platforms and MLPA kit used, definition of CNV calls and the selection
of CHD patients included in the studies. Hightower et al. investigated
173 isolated CHD cases using whole-genome custom-designed oligo-
nucleotide array with>44,000 probes and detected copy number
changes in 50/173 (28.9%) patients (Hightower et al., 2015). Richards
et al. recruited 20 children with syndromic CHD and compared them
with 20 children with isolated CHD. They used high resolution whole
genome array containing 385,000 oligonucleotide probes. They de-
tected a 25% rate of CNVs in the population with syndromic CHD but
none in the population with isolated CHD (Richards et al., 2008). Kim
et al. investigated a prospective cohort of non-syndromic CHD patients
(n=422) and detected a higher burden of potentially pathogenic CNVs
compared to pediatric controls (12.1% vs. 5.0%, P=0.00016) (Kim
et al., 2016). Referring to usage of MLPA for detection of CNVs Mutlu
et al. screened 45 patients with cardiac septal defects for CNVs using
the MLPA P-311 kit and identified three CNVs (n=3/45, 6.66%) at
22q11.2 region causing DiGeorge syndrome (Mutlu et al., 2018). In an
other study, GATA4 and GATA3 genes were investigated by SALSA
P234-MLPA kit to explore pathogenic CNVs in a non-syndromic CHD
cohort (n=161). The patients did not show any CNV in the examined
genes (Guida et al., 2010). Erdogan et al. (Erdogan et al., 2008) re-
ported 17% detection rate for isolated and syndromic CHD, while
Breckpot et al. (Breckpot et al., 2010) described 3.6% for isolated and
19% for syndromic CHD. Sorensen et al. (Sorensen et al., 2012)
screened 402 patients with CHD using MLPA and identified CNV in
3.2% of them.
In case No 1. array CGH clarified and refined the patient’s kar-
yotype, that confirmed the diagnosis of Cri du chat syndrome, also
known as 5p deletion syndrome. Ring chromosome 5 is a rare cytoge-
netic presentation of Cri du chat syndrome, only a few cases have been
reported (Basinko et al., 2012). Approximately 15–20% of affected in-
fants have CHD, the most common heart defect is PDA as it was in our
patient. Currently there is no clear understanding of the genomic cause
of heart defects (Hills et al., 2006). Regarding the sSMC, that originated
from chromosome 15 according to multicolor FISH, the microarray
analysis did not identify any coding region of it indicating no pheno-
typic consequences of its presence.
In patient No 2. microarray revealed that the genomic loss of the
long arm of chromosome 6 is a large, 18.753 kb interstitial deletion
with breakpoints at 6q21 and 6q23.2. This chromosome aberration
encompass the 6q21q22 region that is responsible for a rare, unique
„6q21q22 deletion syndrome” associated with variable congenital
anomalies, intellectual disability (ID), hypotonia, growth retardation
and facial dysmorphism. Three different groups of chromosomal
Fig. 1. Genetic results of case No 1. (A) G-banded karyogram of the patient ring chromosome and sSMC are indicated by arrows. (B) Multicolor FISH result showing
the ring chromosome originated from chromosome 5 (red) and sSMC derived from chromosome 15 (purple) (C) Metaphase FISH result using locus specific probe
combination for Cri du chat (5p15.2) (fusion signal) and SOTOS regions (5q35) (green signal). Cri du chat locus is missing from the ring chromosome 5 (D). Array
CGH result of the proband showing deletion of 5p15.33p13.2 with coordinates 113,576-34,700,951. Signal intensity is plotted on a log2 scale, the deleted segment is
shown as a red bar. B-allele frequences confirm the deletion (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article).
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abnormalities have been described as pathogenetic factor: A or prox-
imal (6q11-q16); B or middle (6q15-q25); C or terminal (6q25-qter).
Toschi et al. (Toschi et al., 2012) have reported an overlapping phe-
notype between patients with acro-cardio-facial syndrome (ACFS) with
type B deletion. ACFS syndrome (MIM # 600460) is a condition char-
acterized by CHD, split hand/foot malformations, facial anomalies, cleft
lip/palate, genital anomalies and ID. Our patient does not exhibit
clinical symptoms of ACFS, only CHD. Concerning cardiac abnormal-
ities the previously reported cases shared the deleted region from 113
to 114.5 Mb including the MARCKS, HDAC2 and GJA1 genes having
important role in regulation of cardiac morphogenesis (Rosenfeld et al.,
2012). In our case the deleted region includes all three genes explaining
the patient’s cardiac phenotype.
In case No 3. array CGH revealed partial deletion of 4q35 and du-
plication of 6q25 regions due to unbalanced translocation. Terminal
deletion of chromosome 4q is a rare event, about 10–20% are the un-
balanced product of a parental reciprocal translocation with con-
comitant partial duplication of the partner chromosomal segment.
Terminal deletion cases present a broad phenotypic range including
intellectual disability, developmental delay, CHD, cleft palate, cranio-
facial dysmorphism and skeletal abnormalities. CHDs were mapped to
two separate regions on 4q35, encompassing causative genes TLL,
HAND2, PDLIM3 and SORBS2 that are involved in cardiac morpho-
genesis (Vona et al., 2014). Our patient’s phenotype is consistent with
the characteristic features of terminal 4q deletion syndrome. The
critical region for CHD at 4q35.1 is identical to that in our patient and
the deleted region contains all of the aformentioned genes. In case of
unbalanced translocation status, the patient has both partial deletion
and partial duplication due to the mispairing of translocated chromo-
somes. In our case the duplication of the distal long arm of chromosome
6 (from 6q25 to 6qter) can result in additional phenotypic abnormal-
ities. Pivnick E et al. (Pivnick et al., 1990) have summarized the clinical
consequences of partial duplication of 6q including craniofacial and
cardiac anomalies, joint contractures and webbed-neck.
In two siblings 8p23.1 duplication was detected. In case No 4. the
CNV was identified by microarray, in patient No 5. the imbalance was
revealed using MLPA. The 8p23.1 duplication syndrome is an ultra rare
recurrent genomic condition, with an estimated prevalence of 1 in
58.000. Twenty four, molecularly characterized cases have been re-
ported until now, most of them being sporadic (Barber et al., 2015). The
syndrome results from a core 3.68 Mb duplication grouped into telo-
meric, medial, and centromeric 8p23.1 segments. This interval lies
between the olfactory receptor/defensin repeats REPD (REPeat Distal)
in distal 8p23.1 and REPP (REPeat Proximal) in proximal 8p23.1. These
repeat sequences predispose to non-allelic homologous recombination
and recurrent de novo 8p23.1 deletions and duplications. The 8p23.1
duplication syndrome has a variable phenotype with three relatively
common features of developmental delay and/or learning difficulties,
CHD and a degree of mild dysmorphism that may be minimal (Weber
et al., 2014; Yu et al., 2011). Congenital heart disease is found in about
Fig. 2. Cytogenetic and array CGH result of case No 3. (A) G-banded karyogram of the proband. The derivative chromosome 4 is designated by an arrow. The
patient’s karyotype: 46,XX,der(4)t(4;6)(q34.3;q25.1). (B) Microarray data of the patient. A 12.15 Mb deletion at chromosome 4q34.3q35.2 (178,807,365-
190,957,460). (C) A 16.95 Mb duplication at chromosome 6q25.1q27 (150,485,038-167,439,226). Signal intensity is plotted on a log2 scale, the deleted segment is
shown as a red bar. B-allele frequences confirm the deletion (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article).
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25% of cases. The core region contains 27 genes and 5 microRNAs of
which GATA4, TNKS, SOX7, and XKR6 are dosage sensitive genes, their
increased expression accounts for some symptoms of the phenotype.
GATA4 in concert with SOX7 might cause congenital heart disease
(Barber et al., 2015). The duplicated region in case No 4. (3.842 kb)
covers the previously defined critical interval (3.68 Mb), so are the
clinical features overlapping: assymetry of the face and skull, epicanthic
fold, deep nasal root, long philtrum, low-set ears, retrognathism. In
Fig. 3. MLPA results of case No 5. (A) and No 6. (B). Chromosomal locations are displayed on the x-axis and y-axis represent dosage quotient (DQ). Normal copy
number is between 0.65 to 1.3. (A) Blue dots show a heterozygous duplication of three genes (PPP1R3B, MSRA, GATA4) at chromosome 8p23.1. (B) Red dots
represent deletion of the entire 22q11.21 region (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article).
O. Nagy, et al. Journal of Biotechnology 299 (2019) 86–95
92
addition, poor mimics, poorly formed, but not prominent ear lobes and
hypospadiasis characterise his clinical appearance. Coarctation of the
aorta was discovered and urgently corrected surgically at two weeks of
age. Neurologically, the patient is developing well and receives normal
education in kindergarten. Case No 5. is the sister of the patient No 4.
She was referred to clinical geneticist at the age of 1.5 years because of
positive family history, mild dysmorphic features and CHD. Using
MLPA analysis the duplication of three genes (PPP1R3B, MSRA,
GATA4) at the 8p23.1 region was detected. These genes are located in
the telomeric, medial and centromeric part of the core critical region of
the 8p23.1, presuming that the duplicated region is similar to that
identified in her brother. Although parental samples are not available
for genetic investigation, we assume that the genetic imbalance in the
siblings is familiar. The increased expression of GATA4 and SOX7 genes
was sufficient for the CHD in both cases. The lack of apparent additional
phenotypic consequences of the duplication may be attributed to the
variable penetrance and expressivity of this syndrome. It is possible that
microduplication of one or more of the affected genes exert their effects
via a network and that variable penetrance reflects compensatory me-
chanisms found in regulatory transcription factor networks
(Weischenfeldt et al., 2013).
DiGeorge syndrome (MIM # 188400) was recognized in two pa-
tients (No 6., 7.). In the absence of characteristic clinical symptoms,
such as immundeficiency, a correct diagnosis of the DiGeorge syndrome
had not been made before the MLPA testing in case No 6. The patient
was diagnosed with isolated TOF for 16 years. In case No 7. the thymus
hypoplasia with TOF indicated the diagnosis of DiGeorge syndrome at
the age of 1 month. 22q11 deletion caused DiGeorge syndrome is the
most common microdeletion syndrome, with prevalence of 1:3000-
6000 live births, although it is likely to be under recognized because of
its clinical variability and heterogeneity (Oskarsdottir et al., 2004).
Many patients have CHD, thymic hypoplasia, developmental delay,
learning difficulties, psychiatric disorders, facial dysmorphism, renal
and eye anomalies, hypoparathyroidism, and skeletal defects. The
22q11.2 region has several blocks of low copy repeats (LCRs) leading to
non-allelic homologous recombination with both duplications and de-
letions. 22q11.2 deletion occurs as a de novo 1.5–3 Mb deletion in most
individuals, while approximately 5% are inherited (McDonald-McGinn
et al., 2001). There are different explanations for the very variable
phenotype: 1) the existence of other genetic variations in the genome,
in addition to the deletion that act as modifiers, 2) the occurrence of
stochastic events during embryogenesis, 3) the existence of environ-
mental exposures in pregnancy (Morrow et al., 2018). The variable
expressivity of DiGeorge syndrome may explain the misdiagnosis of our
patient No 7. Delineating syndromic from non-syndromic CHD can be
problematic especially when most of the symptoms may not manifest,
therefore genetic testing apparently isolated CHD patients with array
CGH or MLPA can be clinically very useful (Erdogan et al., 2008). Some
authors suggest that the array methodology should be used as the first
test for newborn carriers of congenital defects, such as CHD (Monteiro
et al., 2017).
The advent of contemporary genomic technologies are accelerating
of discovery of genetic causes of CHD that is not only a fundamental
research, it has a vital role in the healthcare of the affected individuals.
Identifying a genetic cause of CHD is relevant for clinicians caring for
child or adult with CHD because (1) early diagnosis of syndromic CHD
allow early comprehensive care (2) helps assessing risk for neurode-
velopmental delays (3) providing more accurate prognosis for the CHD
and outcomes of interventions (4) assessing recurrence risk for the
offsprings of affected parents and first degree relatives.
This is the first report studying CNVs in a cohort of CHD patients in
Hungary. In our study we detected pathogenic genomic imbalances in
Fig. 4. Diagnostic pathway for determination of CNVs in syndromic congenital heart diseases.
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21% (7/33) of syndromic CHD patients, this detection rate is similar to
those reported in other populations. Moreover, four clinically relevant
rare CNV different from the 22q11 deletion were identified among the
syndromic patients studied. Rare, pathological CNV with intrafamilial
recurrence in one are also reported, supporting expert opinions to apply
array CGH as the first–tier test even in apparently mild clinical cases of
congenital malformations with or without developmental delay.
Searching for point mutations in CHD associated genes using next-
generation sequencing is aimed to reveal genetic background of our
CNV negative cases. G-banding, FISH and MLPA may still have a role in
the diagnostic workflow of CHD cases, requiring a more detailed and
careful phenotyping. Depending on the availability of array CGH the
most beneficial diagnostic pahway for CHD patients is summarized in
Fig. 4.
Our results confirm the previously published data that pathogenic
CNVs are more common in syndromic CHD cases compared to isolated
ones. Based on our experience the occurence of causative CNVs is
higher with complex CHD phenotypes (e.g. tetralogy of Fallot). The
reported data emphasize the importance of further clarification of cy-
togenetic abnormalities by array CGH to explore a more detailed gen-
otype-phenotype correlation. Our results show that using array CGH
and MLPA was highly effective in the detection and refinement of
clinically significant chromosomal abnormalities in individuals with
syndromic CHD.
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